Ribaxamase - Synthetic Biologics

Drug Profile

Ribaxamase - Synthetic Biologics

Alternative Names: Kymerase; P3A; SYN-004 - Synthetic Biologics; Synthetic Bacillus licheniformis isoenzyme - Synthetic Biologics

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsat Therapies
  • Developer Synthetic Biologics
  • Class Aminohydrolases; Anti-infectives
  • Mechanism of Action Beta lactamase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium-difficile-infections; Diarrhoea

Most Recent Events

  • 23 Apr 2018 Synthetic Biologics plans to initiate phase III trials for the Clostridium difficile infections (Prevention) in USA in the the second half of 2019
  • 20 Apr 2018 Synthetic Biologics, in collaboration with the US FDA, voluntarily withdrew the Breakthrough Therapy status for Clostridium difficile infections (Prevention) in USA
  • 01 Nov 2017 Synthetic Biologics plans collaborative discussions with the US FDA for drug development plan and regulatory pathway for marketing approval of ribaxamase in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top